FDA Legislative Watch: New Web Site Tracks FDA/Capitol Hill Developments

FDA Legislative Watch: New Web Site Tracks FDA/Capitol Hill Developments

Rockville, MD, August 3, 2007 - FDC Reports, Inc., publisher of "The Pink Sheet" a leading biomedical industry news resource, announces the launch of FDA Legislative Watch (http://www.fdalegislativewatch.com), a new beta Web site dedicated to understanding current FDA reform initiatives.

FDA Legislative Watch is written specifically for biomedical industry professionals who need to understand how current legislative developments will affect their business.

FDA Legislative Watch features complimentary coverage from FDC publications including "The Pink Sheet," "The Gray Sheet" and more.

Unlike other online resources, FDA Legislative Watch features highly insightful, original reporting on some of today's hottest legislative issues, including: follow-on biologics, drug safety, food safety, DTC advertising, patent reform, medical devices (MDUFMA), FDA Revitalization Act (PDUFA) and more.

FDA Legislative Watch helps readers stay on top of the latest legislative efforts to reform the FDA with: complimentary news and analysis about legislative developments that affect FDA-regulated businesses; complimentary weekly email newsletters and legislative alerts; complimentary archives and online search; and a complimentary round-the-clock newsfeed featuring FDA legislative news from the Web.

Readers may register online at http://www.fdalegislativewatch.com

For more information, please contact Sean Smith at se.smith@elsevier.com or call 240-221-4535.

About F-D-C Reports

FDC Reports provides up-to-date information about the worldwide health care industry via its publications including "The Pink Sheet"®, "The Gray Sheet"®, "The Rose Sheet"®, "The Tan Sheet"®, and Pharmaceutical Approvals Monthly. The publications are read extensively by pharmaceutical and healthcare executives, policy-makers, and analysts seeking to understand the developments affecting the U.S. regulation and marketing of healthcare products and services. FDC Reports has one of the largest, most experienced, and most respected editorial teams reporting on the latest regulatory, legislative, and business news affecting the U.S. drug, biotechnology, medical device, nonprescription drug, nutritionals, and cosmetics industries.

FDC Reports, Inc. is part of Elsevier. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com < http://www.reed-elsevier.com >.

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).